论文部分内容阅读
聚腺苷酸二磷酸核糖转移酶(Poly(ADP-ribose)polymerase,PARP)抑制剂是一种蛋白质翻译后的DNA修复酶,其在癌症治疗中的作用机制即针对特定的DNA修复途径通过合成致死效应杀伤肿瘤细胞。PARP抑制剂不但能够作为化疗增敏剂,单独使用也能选择性杀伤DNA修复缺陷的肿瘤细胞,如乳腺癌易感基因1/2(breast cancer susceptibilitygene-1/2,BRCA1/2)缺陷的卵巢癌细胞。大量的临床试验证明:该类药物毒副作用小,效果明确且短期耐受性良好,对于癌症治疗前景广阔。本文主要对PARP抑制剂的原理及其在上皮性卵巢癌中的研究进展进行综述,最后对其应用前景作出展望。
Poly (ADP-ribose) polymerase (PARP) inhibitor is a protein post-translational DNA repair enzyme whose mechanism of action in the treatment of cancer is to target specific DNA repair pathway through the synthesis of Lethal effect kill tumor cells. PARP inhibitors not only act as chemosensitizers, but can also selectively kill tumor cells deficient in DNA repair, such as breast cancer susceptibility gene-1/2 (BRCA1 / 2) -deficient ovaries cancer cell. A large number of clinical trials show that: the side effects of such drugs, the effect is clear and short-term well-tolerated, broad prospects for the treatment of cancer. This article mainly summarizes the principle of PARP inhibitor and its research progress in epithelial ovarian cancer. Finally, the prospect of its application is prospected.